Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Ramin Nazarian, Hubing Shi, Qi Wang et al. · Nature · 2010
Cited by 2,192 works. doi:10.1038/nature09626
Authors
- Ramin Nazarian
- Hubing Shi
- Qi Wang
- Xiangju Kong
- Richard Chikara Koya
- Hane Lee
- Zugen Chen
- Mi‐Kyung Lee
- Narsis Attar
- Hooman Sazegar
- Thinle Chodon
- Stanley F. Nelson
- Grant A. McArthur
- Jeffrey Alan Sosman
- Antoni Ribas
- Roger S. Lo
References
- Mutations of the BRAF gene in human cancer
- Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
- RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
- Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
- Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
- RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
- MEK1 mutations confer resistance to MEK and B-RAF inhibition
- V600E BRAF is associated with disabled feedback inhibition of RAF–MEK signaling and elevated transcriptional output of the pathway
- Elevated CRAF as a Potential Mechanism of Acquired Resistance to BRAF Inhibition in Melanoma